We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
-7.01%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$880M
AUM Growth
-$133M
Cap. Flow
-$37.2M
Cap. Flow %
-4.23%
Top 10 Hldgs %
31.67%
Holding
96
New
7
Increased
26
Reduced
40
Closed
10

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$9.09M
2
BSX icon
Boston Scientific
BSX
+$8.75M
3
TMO icon
Thermo Fisher Scientific
TMO
+$7.35M
4
HUM icon
Humana
HUM
+$7.34M
5
RPRX icon
Royalty Pharma
RPRX
+$6.15M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$16.1M
2
CNC icon
Centene
CNC
+$15.7M
3
MCK icon
McKesson
MCK
+$10.2M
4
LLY icon
Eli Lilly
LLY
+$10.1M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.43M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
2 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
1
Cigna
CI
$73.7B
$29.3M 3.32%
111,000
-1,000
-0.9% -$258K
LLY icon
2
Eli Lilly
LLY
$1.02T
$29.2M 3.32%
90,000
-33,500
-27% -$10.1M
ABBV icon
3
AbbVie
ABBV
$443B
$29.1M 3.31%
190,000
-5,000
-3% -$764K
UNH icon
4
UnitedHealth
UNH
$376B
$28.8M 3.27%
56,000
-2,000
-3% -$1M
PFE icon
5
Pfizer
PFE
$143B
$28.3M 3.22%
540,000
+17,500
+3% +$892K
ELV icon
6
Elevance Health
ELV
$81.5B
$27.5M 3.13%
57,000
+10,801
+23% +$5.34M
BSX icon
7
Boston Scientific
BSX
$69.5B
$27M 3.07%
725,000
+215,000
+42% +$8.75M
CVS icon
8
CVS Health
CVS
$133B
$26.9M 3.05%
290,000
+55,000
+23% +$5.37M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$121B
$26.8M 3.04%
95,000
+5,500
+6% +$1.47M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$25.9M 2.95%
325,299
-10,538
-3% -$998K
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.9B
$25M 2.84%
160,000
-21,976
-12% -$3.38M
MRK icon
12
Merck
MRK
$322B
$24.2M 2.75%
265,000
+40,000
+18% +$3.55M
MCK icon
13
McKesson
MCK
$100B
$20.6M 2.33%
63,000
-32,000
-34% -$10.2M
TMO icon
14
Thermo Fisher Scientific
TMO
$213B
$20.2M 2.29%
37,100
+13,350
+56% +$7.35M
HUM icon
15
Humana
HUM
$43.7B
$20.1M 2.29%
43,000
+16,500
+62% +$7.34M
ABT icon
16
Abbott
ABT
$183B
$18.5M 2.1%
170,000
+80,000
+89% +$9.09M
ABMD
17
DELISTED
Abiomed Inc
ABMD
$18.1M 2.05%
73,000
+5,000
+7% +$1.35M
JNJ icon
18
Johnson & Johnson
JNJ
$618B
$17.8M 2.02%
100,000
-13,000
-12% -$2.32M
COR icon
19
Cencora
COR
$60.6B
$17.7M 2.01%
125,000
+17,000
+16% +$2.6M
ISRG icon
20
Intuitive Surgical
ISRG
$127B
$14.1M 1.6%
70,000
+17,500
+33% +$4.11M
THC icon
21
Tenet Healthcare
THC
$20.5B
$13.7M 1.56%
261,000
+58,000
+29% +$4.04M
DHR icon
22
Danaher
DHR
$137B
$13.7M 1.56%
60,912
+22,560
+59% +$5.2M
AXNX
23
DELISTED
Axonics, Inc. Common Stock
AXNX
$13.6M 1.55%
240,000
– –
SWAV
24
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$13.6M 1.54%
70,978
+16,178
+30% +$2.86M
MDT icon
25
Medtronic
MDT
$109B
$13.5M 1.53%
150,000
-10,000
-6% -$1.01M
1
2 3 4

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Rhenman & Partners Asset Management held 96 positions worth $880M, down 13% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $37.2M in Q2 2022, closing 10 positions and reducing 40 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $16.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Royalty Pharma worth $6.31M.

  • Rhenman & Partners Asset Management's largest Q2 2022 buy was Royalty Pharma: 150,000 shares worth $6.31M.
  • Rhenman & Partners Asset Management added most to Abbott in Q2 2022, an estimated $9.09M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2022 reduction was McKesson, cutting an estimated $10.2M.
  • Rhenman & Partners Asset Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $16.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 32% of its $880M portfolio in Q2 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 10 in Q2 2022.
  • Rhenman & Partners Asset Management's portfolio value fell 13% quarter-over-quarter to $880M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.